Current Opinion in Pediatrics - Abstract: Volume 15(6) December 2003 p 579-585 Novel therapies in pediatric rheumatic diseases.

[Guest guest]

Current Opinion in Pediatrics: Volume 15(6) December 2003 pp 579-585

Novel therapies in pediatric rheumatic diseases

Chira, ; Sandborg, Christy I.

Department of Pediatrics, Division of Rheumatology, Stanford University

School of Medicine, Stanford, California, USA

Correspondence to Christy I. Sandborg, MD, Department of Pediatrics,

Division of Rheumatology, 300 Pasteur Drive, Suite G310, Stanford, CA

94305-5208, USA

Tel: 650-723-8295; e-mail: sandborg@...

Abstract

Purpose of review: Better understanding of the etiology of autoimmune

diseases and their progression has brought about numerous novel therapies

used in the treatment of pediatric rheumatic diseases. The introduction of

biologic agents such as tumor necrosis factor inhibitors has changed how we

approach and manage autoimmune diseases. This has led to a proliferation of

other therapies targeting specific inflammatory processes evident in many

rheumatic illnesses, with hopes of improving efficacy and decreasing adverse

effects from treatment.

Recent findings: Clinical studies demonstrate safety and efficacy of these

newer medications in both adults and children. Although most of the novel

therapies have been studied primarily in the adult rheumatic population,

many are being evaluated in children in randomized controlled and open label

trials as well. Long-term results are being collected regarding these newer

regimens in both adults and children.

Summary: This review looks at the risks and benefits of the variety of novel

therapies including the new biologics, immunosuppressives, and stem cell

transplantation currently being used in rheumatic conditions. Using these

new therapies along with traditional antirheumatic medications, pediatric

rheumatologists intervene to control disease early and more effectively to

prevent long-term damage and complications.